circio

Disruptive circRNA technology for genetic medicine

R&D webinar
29 November 2023

Important notice and disclaimer

This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the results of operations and the financial condition of Circio ASA and the Circio Group. Such forward-looking statements reflect the current views of Circio and are based on the information currently available to the company. Circio cannot give any assurance as to the correctness of such statements.

There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and know-how; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's products; risks that research and development will not yield new products that achieve commercial success; risks relating to the company's ability to successfully commercialize and gain market acceptance for Circio's products; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks associated with technological development, growth management, general economic and business conditions; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.

Today's presenters

Dr Erik D Wiklund

Chief Executive Officer

Co-discoverer of circRNA, Pharma consultant at McKinsey & Co and various commercial and R&D roles in biotech, Previously CFO and CBO of Targovax

PhD Cancer epigenetics and RNA biology

Dr Victor Levitsky

Chief Scientific Officer

Deeply experienced tumor immunology scientist from academia and industry, incl Karolinska Institute, John´s Hopkins, Roche and Molecular Partners

MD, PhD Virology and tumor biology

Dr Thomas B Hansen

VP & Head of Research

World-leading pioneer and co-discoverer of circular RNA; 10 years as group leader at Aarhus University in RNA biology and bioinformatics

PhD Molecular and RNA biology

Dr Alexander Wesselhoeft

Dir of RNA Therapeutics, Mass General Brigham

Circular RNA pioneer and founder of ORNA Therapeutics

Optimized circular RNA for in vivo protein expression

PhD Molecular and RNA biology

circio

Agenda

1 Introduction
Dr Erik Digman Wiklund - CEO

15 min

2 Circular RNA Technology - Advances and Challenges
Dr R Alexander Wesselhoeft – Dir of RNA Therapeutics, Mass General Brigham

30 min

3 circVec technology overview
Dr Thomas B Hansen – VP & Head of Research

20 min

4 Development Strategy
Dr Victor Levitsky- CSO

15 min

1

Introduction

Dr. Erik Digman Wiklund, CEO

circRNA will disrupt gene therapy and vaccines by improving potency and adding novel functionality

Extended RNA durability

Enhanced protein expression



circRNA is resistant to exonuclease degradation, leading to significantly prolonged half-life vs. mRNA within cells



microRNA sponging

Regulatory functionality

circRNA is gaining momentum as a superior mRNA platform

Feb 2021
ORNA
$80M
Series A

Jul 2022
therorna 圆因生物
$42M
Series A

Aug 2022
ORNA
$221M
Series B

Oct 2022
GINKGO BIOWORKS, Circularis
Undisclosed
M&A

Aug 2023
Pfizer, CirCode
$30M
Series A

Series A+B
laronde
$490M
May/Aug 2021

Licensing
ORNA, MERCK
$150M Upfront
$3,5B Total deal value
Aug 2022

Series A
ORBITAL THERAPEUTICS
$270M
April 2023

Series A
ReNAgade THERAPEUTICS
$300M
May 2023

The discoverers of circRNA work for Circio

Dr Thomas B Hansen

Dr Erik D Wiklund

nature 6,373 citations

Published: 27 February 2013

Natural RNA circles function as efficient microRNA sponges

Thomas B. Hansen, Trine I. Jensen, Bettina H. Clausen, Jesper B. Bramsen, Bente Finsen, Christian K. Damgaard & Jørgen Kjems

THE EMBO JOURNAL — EMBOpress 30 September 2011 922 citations

CURRENT ISSUE ABOUT INFORMATION ARCHIVE ALERTS SUBMIT

miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA

Thomas B Hansen, Erik D Wiklund, Jesper B Bramsen, Sune B Villadsen, Aaron L Statham, Susan J Clark, Jørgen Kjems

nature reviews genetics 2,291 citations

Review Article | Published: 08 August 2019

The biogenesis, biology and characterization of circular RNAs

Lasse S. Kristensen, Maria S. Andersen, Lotte V. W. Stagsted, Karoline K. Ebbesen, Thomas B. Hansen & Jørgen Kjems

circVec – Circio`s proprietary vector system for intra-cellular protein expression



circVec
DNA or viral
vector

Inject

circRNA
biogenesis

Intra-cellular
protein expression

The central dogma of molecular biology

DNA → TRANSCRIPTION → **mRNA** → TRANSLATION → **PROTEIN**







- Genetic Code
- Recipe for Proteins
- Durable (“eternal”) in the cell nucleus

- Instruction to generate protein
- Transient: 6-24h in cell cytoplasm

- Performing specific function
- Can be structural or chemical

With new technology, mRNA can be made circular

mRNA

Circular RNA

With new technology, mRNA can be made circular



mRNA

- 5'cap-dependent initiation of translation
  - Rate-limiting step
- Short half-life
  - Hours to days
- 5`cap & 3'poly-A tail – accessible for exonuclease degradation

Circular RNA



- IRES-mediated initiation (Internal Ribosome Entry Site)
  - More efficient than 5' cap-dependent initiation
- Extended half-life
  - Days to weeks
- No 3' or 5' end → exonuclease resistance

2

KOL presentation

Dr. Alexander Wesselhoeft

3

circVec overview

Dr. Thomas Birkballe Hansen
VP & Head of Research

Circular RNA – a natural design



High natural prevalence of circular RNA in all eukaryotes, particularly in humans

Why use circRNA?

Growth-decay model:

Expression

$P = production\ rate$

$$X(t) = Ce^{-Dt} + \frac{P}{D}$$

$$D = decay\ rate = \frac{\log_e 2}{T½}$$

Gene expression is determined by production rate and decay rate.

Two ways to increase expression



circRNAs are significantly more stable than linear mRNA

circio

Bioinformatic simulation demonstrating advantage of vector-expressed circRNA vs. mRNA

Temporal vector-based RNA expression dynamics; circRNA vs. mRNA



Input assumptions for simulation:

Non-dividing target cells

mRNA production:	10 molecules / hr
mRNA half-life:	9 hrs *
circRNA production:	2 molecules / hr *20% of mRNA rate*
circRNA half-life:	135 hrs * *15x mRNA ½-life*

→ circRNA translation 5x mRNA rate gives >25x peak protein expression*

* Based on circVec experimental data

circVec is based on nature´s best design



Expression of human endogenous circRNA
NGS analysis of 300+ RNAseq datasets



Maximum biogenesis-rate of endogenous circRNA

Screening of most effective natural sequences



IR1 cassette design shows best circRNA biogenesis

Validation of circRNA biogenesis

IR-dependent signal





No production without IR element

RNAseR resistant





Resistance towards exonucleolytic degradation

IRES: enabling cap-independent translation from circular RNA

circRNAs are translated in a cap-independent manner



Protein expression, Western blot



IRES element is required for circRNA translation

Design rules: Cassette composition is critical

De-circularize into linear DNA cassette





Optimization scheme



circio

Optimizing flanking IR improves circRNA biogenesis

circRNA expression, RT-qPCR



eGFP expression from circRNA, western blot



Modification of downstream inverted repeat (IR) element enhances both circRNA biogenesis and protein expression

IRES optimization results in ~10x higher protein expression

2 - Optimize translation

circVec design optimization, protein expression level @48h post-transfection



circVec v2.0 achieves up to 10x[1] higher protein yield than v1.0 design

1 Level of improvement in range of 3-10x depending on cell type

circVec substantially outperforms the expression level and durability of mRNA-based systems

Increased expression level

Prolonged durability

Enhanced therapeutic potency

"Due to its significant advantages, circRNA systems can be expected to replace mRNA-based expression for DNA format therapeutics in the future – just as synthetic circRNA can be expected to replace current mRNA formats"

Dr. Alex Wesselhoeft

Scientific founder
oRNA Therapeutics

circVec vs. mRNA luciferase reporter expression; time course



Characterizing circVec v2.1 performance in vivo





Realtime monitoring ongoing

Efficient circRNA expression established in mouse model demonstrating progressive accumulation

Adding more functionalities to circVec



circVec

Expression of missing protein in loss-of-function scenarios!

Removal of protein in gain-of-function scenarios?

Remove-and-Replace design!

Remove-and-Replace concept enables expression of missing protein while depleting aberrant transcripts

circVec-*remover*

Expression of missing protein in loss-of-function scenarios!



Loss-of-function protein expression

Removal of protein in gain-of-function scenarios!



Sequence-specific gain-of-function target cleavage

Remove-and-Replace concept enables expression of missing protein while depleting aberrant transcripts

circVec-*remover*

Expression of missing protein in loss-of-function scenarios!

CircRNA expression unaffected by remover modality



Removal of protein in gain-of-function scenarios!

Effective depletion of target gene by *remover*



Technical development status

- ✓ Substantially optimized circRNA biogenesis and protein expression
- ✓ Multifunctional *Remove-and-Replace* concept established
- ✓ In-vivo validation ongoing in multiple settings
- ✓ Now testing circVec 2.1 in therapeutically relevant applications

4

R&D Strategy

Dr. Victor Levitsky - CSO

Major opportunities identified for the circVec platform in gene therapy and vaccines

Current focus areas

Rare disease

"Remove-and-replace" concept with durability and safety advantages

-

Major long-term potential

Vaccines

Enhanced potency, single dose vaccine concept with simplified administration

-

Early partnering option

Cancer gene therapy

Efficient and durable expression of therapeutic proteins in solid tumors

-

Unique oncology concept

Designed for intra-cellular circRNA supply, durable protein expression and targeted regulatory functionality

Broad analysis performed to identify target rare diseases suitable for circVec approach



Initial Screening

- Therapeutic Focus: Rare genetic disorders
- Development Stage: Clinical or Market validation achieved

1st Prioritization Criteria

- Etiology: monogenic disorders only (exclude polygenic disorders)
- In vivo validation: availability of suitable in vivo models

2nd Prioritization Criteria

- Epidemiology: From Moderate (1/50,000) to High (<1/2,000)
- Gene size: ORF $\leq$ 4,500 Kb

Indication Prioritization Final Step

Identified short-list of eight monogenic disorders with strong fit for circVec

Short-list of 8 rare monogenic disorders particularly suitable for circVec approach

Lead Indication

Alpha-1 Antitrypsin Deficiency (AATD)

Second priority

Ornithine Transcarbamylase Deficiency (OTCD)

Citrullinemia Type I (CTLN1)

Argininosuccinate Synthetase Lyase Deficiency (ASLD)

Third priority



Pompe Disease

Wilson Disease



Glycogen Storage Disease 1A



Tyrosinemia Type I

Commercial and regulatory assessment ongoing

Lead indication: Alpha-1 antitrypsin deficiency (AATD)

AATD is a major unmet medical need manifested in liver and lung



- Lack of functional AAT protein
- Emphysema and/or chronic bronchitis

- Accumulation of toxic mutant protein
- Cirrhosis

Patients with moderate to severe AATD

120K in EU

75K in US

Current treatment options

Lung-associated AATD

- Replacement therapy with an alpha-1 proteinase inhibitors
- Weekly IV infusions
- Bronchodilators and inhaled steroids used for mild symptoms

Liver-associated AATD

- No approved therapeutics
- Liver transplantation is the only treatment alternative in severe cases

circVec "Remove-and-Replace" concept for AATD

Depleting mutant form and replenishing functional protein by circVec

- *reverses toxic protein accumulation in liver and restores normal function in lung*



circVec v1.0 AAT expression in liver cells



circVec mutAAT knock-down



High dosing requirement is a substantial shortcoming for AAV-based gene therapy

Safety issues
Liver toxicity, innate immunity

High dose = high immunogenicity
No repeat dosing

Manufacturing cost
10^{14} – 10^{15} VPs per dose



AAV: circVec proof-of-concept for gene therapy

vector

Standard mRNA approach

circVec circRNA approach

Shorter durability

RNA

15x durability
5x translation rate

Lower steady-state protein levels

Protein



>25x maximum protein levels

circVec has the potential to substantially boost the potency of AAV-based gene therapy

circVec-based AAV therapy can translate into major improvement in long-term expression dynamics

Temporal AAV-based RNA expression dynamics; circRNA vs. mRNA



* Based on circVec experimental data

Input assumptions for simulation:

Non-dividing target cells

AAV half-life:	365 days
mRNA production:	10 molecules / hr
mRNA half-life:	9 hrs *
circRNA production:	5 molecules / hr
circRNA half-life:	135 hrs * *15x mRNA ½-life*

→ circRNA translation 5x mRNA rate gives >25x peak protein expression*

circVac: AdV circVec system for potent vaccination

Replication-deficient
AdV vector *35kb genome*



circVec inserts
>7kb size feasible



One or more circRNAs
2-6kb size per circRNA

Durable protein or
antigen expression

+RNAi

Additional booster,
miRNA sponging

Non-replicating AdV advantages

- Large cargo capacity 7+ kb, 50% more than AAV vectors
- Opportunity to express multiple circRNAs from one vector
- Potent and well-described for vaccine applications
- Established delivery to muscle and lung (intra-nasal/inhaled)

Upcoming milestones

4Q´23:	circVac v1.0 Spike vaccine *in vivo* data
1Q´24:	circVac v2.0 Flu intra-nasal *in vivo* data
1H´24:	circVac v2.0 Spike vaccine *in vivo* data

Durable expression of COVID Spike protein demonstrated for circVac 1.0

circVac v1.0 COVID Spike expression, RNA and protein level

RNA expression



SPIKE-encoding circRNA accumulates over time

Protein expression



circRNA > mRNA SPIKE protein expression @ 96hr

circVac v1.0 Spike protein *in vivo* experiment ongoing, circVac v2.0 Spike in production

Circio has a unique position in the circRNA field

- Circio is the only significant player in the DNA-format circRNA space

- Enhanced durability and protein expression from circRNA is expected to translate into lower dosing of DNA-format applications, which may solve both potency, toxicity and cost challenges facing current ”gold-standard” gene therapy

- Vector-expressed circRNA has the potential to become the preferred format for any DNA-based therapeutic in the future
  - *Just as synthetic circRNA is expected to become the preferred format for long RNA-based therapeutics in the future*